Commentary| July 01 2022 Clinical Overbasalization Revisited Mayer B. Davidson 0000-0001-9194-8857 Mayer B. Davidson Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: Mayer B. Davidson, mayerdavidson@cdrewu.edu Clin Diabetes 2022;40(3):354–355 https://doi.org/10.2337/cd21-0132 PubMed: 35983420 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation Mayer B. Davidson; Clinical Overbasalization Revisited. Clin Diabetes 1 July 2022; 40 (3): 354–355. https://doi.org/10.2337/cd21-0132 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search Cowart and Carris recently wrote a commentary in Clinical Diabetes (1) defending their definition of overbasalization as occurring in patients with A1C levels >8.0% who are receiving >0.5 units/kg of a basal insulin. Their commentary was written in response to an earlier commentary by me that was also published in this journal (2), in which I challenged their definition, although they did not mention my earlier article in theirs. I had made the case that the appropriate definition of overbasalization is a clinical situation in which basal insulin doses are increased even further after fasting plasma glucose (FPG) targets have been achieved in an attempt to control postprandial glycemia during the day (2). This practice often results in hypoglycemia, usually overnight. Cowart and Carris agreed with that definition describing overbasalization but stated that it was uncommon (not in my experience) and went on to... You do not currently have access to this content.